Results 81 to 90 of about 166,627 (157)

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older

International Journal of Infectious Diseases, 2019
Objective: To assess the long-term safety of MF59-adjuvanted trivalent influenza vaccine (aIIV3; Fluad™) in adults ≥65 years of age. Methods: Data from 36 primary vaccination and 7 re-vaccination Phase I through III trials were analyzed; 7532 subjects ...
Kelly Lindert, Brett Leav, Esther Heijnen, Julia Barrett, Uwe Nicolay   +4 more
doaj   +1 more source

Augmentation of Vaccine-induced Humoral and Cellular Immunity by a Physical Radiofrequency Adjuvant [PDF]

, 2018
Protein/subunit vaccines often require external adjuvants to induce protective immunity. Due to the safety concern of chemical adjuvants, physical adjuvants were recently explored to boost vaccination. Physical adjuvants use physical energies rather than
Cao, Yan, Kakar, Prateek, Zhao, Yiwen, Hossen, Md Nazir, Chen, Xinyuan, Zhu, Xiaoyue, Md Nazir Hossen, Yiwen Zhao, Xiaoyue Zhu, Yan Cao, Prateek Kakar, Xinyuan Chen   +11 more
core   +1 more source

ADJUVANTS OF INFLUENZA VACCINES: NEW POSSIBILITIES OF USING SULPHATED POLYSACCHARIDES FROM MARINE BROWN ALGAE

Вопросы вирусологии, 2019
The review article presents the characteristics of the main adjuvant groups (mineral salts of aluminum, synthetic squalene-based adjuvants - MF59 and AS03, CpG-oligodeoxynucleotides, virosomes, polyoxidonium, sovidone) included in the licensed influenza ...
T. A. Kuznetsova, E. V. Persiyanova, T. S. Zaporozhets, N. N. Besednova   +3 more
doaj   +1 more source

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

, 2012
BACKGROUND: Vaccines against pandemic A/H1N1 influenza are required to protect the entire population. This dose range study aimed to identify priming antigen and adjuvant doses resulting in optimal levels of antibody-mediated protection after primary and
Lattanzi, Maria, Hatz, C., Leroux-Roels, G., Hatz, Christoph, Leroux-Roels, Geert, von Sonnenburg, F., Casula, Daniela, Casula, D., von Sonnenburg, Frank, Lattanzi, M., Hatz C, Leroux-Roels G, Casula D, von Sonnenburg F, Lattanzi M   +14 more
core   +1 more source

Immune mechanisms of protection: can adjuvants rise to the challenge? [PDF]

, 2010
For many diseases vaccines are lacking or only partly effective. Research on protective immunity and adjuvants that generate vigorous immune responses may help generate effective vaccines against such ...
MacLeod Megan KL, Philippa Marrack, Amy S McKee, Marrack, P., Megan KL MacLeod, Marrack Philippa, Kappler, J.W., John W Kappler, MacLeod, M.K.L., Kappler John W, McKee, A.S., McKee Amy S   +11 more
core   +1 more source

Construction and Immune Strategy Optimization of a Vaccine Strain for Influenza A (H5N8) Subtype

Viruses
Multiple subtypes of avian influenza virus (AIV), including H5N1, H5N6, and H5N8 viruses, are currently co-circulating in wild birds and poultry and causing sporadic human infections. Vaccine development is essential for pandemic preparedness.
Shuxia Zhang, Jing Tang, Liqi Liu, Hejiang Wei, Li Xin, Kang Xiao, Jinbo Xiao, Jie Dong, Zi Li, Hongyan Bai, Shuaixing Wang, Wenfei Zhu, Lei Yang, Shumei Zou, Dayan Wang   +14 more
doaj   +1 more source

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

PLoS ONE, 2016
BackgroundThe safety and immunogenicity of SAAVI DNA-C2 (4 mg IM), SAAVI MVA-C (2.9 x 109 pfu IM) and Novartis V2-deleted subtype C gp140 (100 mcg) with MF59 adjuvant in various vaccination regimens was evaluated in HIV-uninfected adults in South Africa ...
Gavin Churchyard, Koleka Mlisana, Shelly Karuna, Anna-Lise Williamson, Carolyn Williamson, Lynn Morris, Georgia D Tomaras, Stephen C De Rosa, Peter B Gilbert, Niya Gu, Chenchen Yu, Nonhlanhla N Mkhize, Tandile Hermanus, Mary Allen, Michael Pensiero, Susan W Barnett, Glenda Gray, Linda-Gail Bekker, David C Montefiori, James Kublin, Lawrence Corey   +20 more
doaj   +1 more source

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

, 2001
Three-hundred and eight outpatient elderly subjects (> or = 65 years) were randomly assigned to receive the MF59-adjuvanted influenza vaccine (FLU-AD; n = 204) or a conventional subunit influenza vaccine (AGRIPPAL S1; n = 104) in order to compare the ...
Pozzi, T., Montomoli, E., Minutello, M., Senatore, F., Podda, A., Gasparini, R., Fragapane, E.   +6 more
core   +1 more source

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2020
Yang J, Zhang J, Han T, Liu C, Li X, Yan L, Yang B, Yang X.   +7 more
europepmc   +1 more source

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to conventional subunit vaccine in elderly subjects.

, 2001
Three-hundred and eight outpatient elderly subjects (> or = 65 years) were randomly assigned to receive the MF59-adjuvanted influenza vaccine (FLU-AD; n = 204) or a conventional subunit influenza vaccine (AGRIPPAL S1; n = 104) in order to compare the ...
GASPARINI, ROBERTO, POZZI T, SENATORE F, MONTOMOLI E, PODDA A., MINUTELLO M, FRAGAPANE E   +6 more
core   +1 more source